Evidence map›Paper›PMID 40404809›Full record

ArticleScientific reports2025

Epigallocatechin-3-gallate binds tandem RNA recognition motifs of TDP-43 and inhibits its aggregation.

Maria Agnese Morando, Vito D'Alessandro, Angelo Spinello, Martina Sollazzo, Elisa Monaca, Raffaele Sabbatella, Maria Concetta Volpe, Francesca Gervaso, Alessandro Polini, Sarah Mizielinska and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria Agnese Morando *Structural Biology and Biophysics Unit, Fondazione Ri.MED, 90133, Palermo, Italy.
Vito D'Alessandro *Structural Biology and Biophysics Unit, Fondazione Ri.MED, 90133, Palermo, Italy.
Angelo SpinelloDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90028, Palermo, Italy.
Martina SollazzoStructural Biology and Biophysics Unit, Fondazione Ri.MED, 90133, Palermo, Italy.
Elisa MonacaStructural Biology and Biophysics Unit, Fondazione Ri.MED, 90133, Palermo, Italy.
Raffaele SabbatellaStructural Biology and Biophysics Unit, Fondazione Ri.MED, 90133, Palermo, Italy.
Maria Concetta VolpeFondazione Ri.MED, 90133, Palermo, Italy.
Francesca GervasoCNR Nanotec-Institute of Nanotechnology, Campus Ecotekne, 73100, Lecce, Italy.
Alessandro PoliniCNR Nanotec-Institute of Nanotechnology, Campus Ecotekne, 73100, Lecce, Italy.
Sarah MizielinskaUK Dementia Research Institute at King's College London, London, UK.
Caterina AlfanoStructural Biology and Biophysics Unit, Fondazione Ri.MED, 90133, Palermo, Italy. calfano@fondazionerimed.com.

Funding

Italian Ministry of University and Research CUP B73C21001300006Programma Operativo Nazionale Ricerca e Innovazione 2014-2020 (CCI 2014IT16M2OP005), Fondo Sociale Europeo, Azione I.1 "Dottorati Innovativi con caratterizzazione Industriale" CUP F85F20000260006
6 · The paper itself

Abstract

Transactive response DNA-binding Protein 43 (TDP-43) aggregation is a key pathological feature in Amyotrophic Lateral Sclerosis and related neurodegenerative diseases. This study investigates the inhibitory effects of Epigallocatechin-3-gallate (EGCG), a polyphenol found in green tea, on TDP-43 aggregation. Using a combination of fluorescence assays, NMR spectroscopy, and computational modeling, we demonstrate that Epigallocatechin-3-gallate significantly delays the nucleation phase of TDP-43 aggregation process, thus inhibiting the formation of TDP-43 aggregates in vitro. Additionally, we proved a direct interaction of the compound with the RNA recognition motifs of TDP-43 and modeled the mechanism of interaction. Our findings reveal that EGCG stabilizes the RRM domains, counteracting aggregation by interfering with the early stages of the amyloidogenic pathway. Furthermore, EGCG's stability under experimental conditions was ensured using reducing agents, highlighting the importance of maintaining its reduced form for reproducible results. These insights underscore the therapeutic potential of EGCG in TDP-43 proteinopathies and provide a foundation for developing targeted treatments for ALS and related disorders.

Indexed as

CatechinDNA-Binding ProteinsProtein AggregatesRNA Recognition MotifAmyotrophic Lateral SclerosisHumansProtein BindingCatechinDNA-Binding Proteinsepigallocatechin gallateProtein AggregatesTARDBP protein, humanALSEGCG stabilityProtein aggregationProtein-ligand interactionRNA-binding proteinsTDP-43

Identifiers

PMID40404809
PMCPMC12098689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.